Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.
Xie. Xingmiao X; Yang. Shuiyuan S; Deng. Shuzhen S; Liu. Yuying Y; Xu. Zhibin Z; He. Binghong B
Key Findings
- Overall GI sideāeffects occurred in about 12% of patients, with nausea being the most common (ā21%) and reduced appetite the least (ā5%).
- Tirzepatide showed the highest risk for nausea and diarrhea among all GLPā1 receptor agonists studied.
- Dulaglutide and lixisenatide had the lowest GI risk, while exenatide was linked to the most vomiting and semaglutide to higher diarrhea rates.
Practical Outcomes
- If you plan to use tirzepatide, expect a higher chance of nausea and diarrhea and consider a slower doseāescalation or antiānausea strategies. For better gut tolerance, you might prefer dulaglutide or lixisenatide, especially if youāre sensitive to GI upset. Monitoring and adjusting based on personal tolerance can improve adherence and overall results.
Summary
A big review of 48 trials (27,729 people) found that the new drug tirzepatide causes more stomach upsetāespecially nausea and diarrheaāthan other GLPā1 drugs used for typeā2 diabetes. Other drugs like dulaglutide and lixisenatide were easier on the gut, while exenatide caused more vomiting and semaglutide gave more diarrhea. This info helps people who experiment with these peptides know which ones might be harder on their digestion.
Abstract
This study aims to evaluate and compare the gastrointestinal adverse effects associated with different GLP-1 receptor agonists (GLP-1RAs) and multi-target analogs in patients with type 2 diabetes mellitus (T2DM) using a Bayesian network meta-analysis. A systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted to identify randomized controlled trials (RCTs) assessing the gastrointestinal adverse events of GLP-1RAs in T2DM patients. Inclusion criteria included adult patients with confirmed T2DM receiving any GLP-1RA, with the outcomes focused on gastrointestinal adverse events such as nausea, vomiting, diarrhea, constipation, dyspepsia, and reduced appetite. Bayesian network meta-analysis was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for the comparison of gastrointestinal side effects among different GLP-1RAs. A total of 48 RCTs involving 27,729 participants were included in the analysis. The overall incidence of gastrointestinal adverse events was 11.66%, with nausea being the most frequent (21.49%) and reduced appetite the least frequent (5.49%). Tirzepatide had the highest risk of inducing nausea and diarrhea, while dulaglutide and lixisenatide had the lowest risks. Exenatide exhibited the highest incidence of vomiting, while dulaglutide showed a lower risk. Semaglutide demonstrated a significantly higher risk of diarrhea compared to other GLP-1RAs. This study highlights significant differences in the gastrointestinal adverse event profiles of various GLP-1RAs. Tirzepatide exhibited the highest risk of gastrointestinal side effects, whereas dulaglutide and exenatide showed relatively better tolerability. These findings provide valuable insights for clinicians to make informed treatment decisions, emphasizing the importance of individualized therapy based on patient tolerance. CRD42024592308.
Study Information
pubmed
2025
2025-09-19T00:00:00.000Z
10.3389/fphar.2025.1613610
77